PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Critical Care Quality Improvement Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Ernest and Julio Gallo Management Program, School of Engineering, University of California, Merced, United States.\', \'Faculty member of Islamic Azad University of Medical Sciences, Tehran, Iran.\', \'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: fzh.dastan@gmail.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1567-5769(21)00679-210.1016/j.intimp.2021.108043
?:hasPublicationType
?:journal
  • International immunopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 34426105
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.051
?:rankingScore_hIndex
  • 94
is ?:relation_isRelatedTo_publication of
?:title
  • Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34426105>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34426105>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all